GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Carmell Corp (NAS:CTCX) » Definitions » Other Net Income (Loss)

Carmell (Carmell) Other Net Income (Loss) : $1.04 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Carmell Other Net Income (Loss)?

Carmell's Other Net Income (Loss) for the three months ended in Mar. 2024 was $0.28 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was $1.04 Mil.

Carmell's quarterly Other Net Income (Loss) increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.76 Mil) but then declined from Dec. 2023 ($0.76 Mil) to Mar. 2024 ($0.28 Mil).

Carmell's annual Other Net Income (Loss) stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.76 Mil).

Carmell Other Net Income (Loss) Historical Data

The historical data trend for Carmell's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell Other Net Income (Loss) Chart

Carmell Annual Data
Trend Dec21 Dec22 Dec23
Other Net Income (Loss)
- - 0.76

Carmell Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only - - - 0.76 0.28

Carmell Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carmell Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Carmell's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Carmell (Carmell) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Carmell Corp (NAS:CTCX) » Definitions » Other Net Income (Loss)
Comparable Companies
TIL CLSD SLDB CRDF MEIP CLNN BIOR IMUX RANI LGVN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Website
https://www.carmellcorp.com
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036